Q-omics provides the consensus-scored SMIM15 profile across patient tissues and cancer cell-line models. SMIM15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SMIM15 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, SMIM15 RNA expression shows 19,795 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, LUAD, and ACC as cancer lineages where SMIM15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM15 survival associations across molecular data types. SMIM15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM15 RNA expression–survival associations across cancer types. High SMIM15 expression shows unfavorable associations in LIHC, KICH, KIRP, LUAD and UVM, but favorable associations in KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SMIM15 RNA expression.
This table summarizes SMIM15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SMIM15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM15 shows higher tumor expression in LUAD, HNSC, KIRC, LIHC, KIRP and STAD. The LUAD box plot shows higher SMIM15 RNA expression in tumor versus normal tissue (log2 FC = +0.866, t-test p < 0.001).
This table shows molecular features associated with SMIM15 in patient tissues and cancer cell lines. In patient samples, SMIM15 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
